A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

NCT07081178 | Terminated

• 2 other identifiers: NN9536-8332U1111-1314-8335
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity. The purpose of this study is to collect data on the effect of Semaglutide under everyday conditions in participants. Participants and doctor had already decided that they will get semaglutide prescribed by doctor, independently of patient's participation in this study. The study will last for 12 months.

Conditions

Obesity

Outcome Measures

Primary Outcomes (1)

• Change in relative body weight

  Percentage (%)

  From baseline to month 6 and month 9

Secondary Outcomes (19)

• Change in relative body weight

  From baseline to month 3 and 12

• Change in body weight

  from baseline to month 3, month 6, month 9 and month 12

• Change in Haemoglobin A1c (HbA1c)

  from baseline to month 3, month 6, month 9 and month 12

• Change in fasting plasma glucose (FPG)

  from baseline to month 3, month 6, month 9 and month 12

• Change in total cholesterol

  from baseline to month 3, month 6, month 9 and month 12

Study Arms (2)

Group A

Participants will be treated with commercially available semaglutide along with lifestyle modification in the routine clinical practice.

Drug: Semaglutide

Group B

Participants with lifestyle modification in the routine clinical practice will be included.

Interventions

Semaglutide DRUG

Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.

Group A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Two groups of participants are planned to be included, one Group (A) with those initiating semaglutide adjunct with lifestyle modification, and the other Group (B) with those only with lifestyle modification.

You may qualify if:

• Male or female, age above or equal to 18 years at the time signing informed consent.
• Body mass index (BMI) more than or equal to (≥) 30 kilogram per meter square (kg/m\^2) with at least one of the following diagnosed obesity-related comorbidities:
• arterial hypertension, pre-diabetes, Obstructive Sleep Apnea (OSA) or coronary heart disease, chronic heart failure, or BMI ≥35 kg/m\^2.
• History of at least one self-reported unsuccessful attempt to lose weight.
• Capable of completing informed consent.
• The decision to initiate treatment with commercially available Wegovy has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.
• Initiation of treatment is not modified in any case due to participant's participation in the study.

You may not qualify if:

• Previous participation in this study (participation is defined as having given informed consent in this study)
• Treatment with an investigational drug within 30 days prior to enrolment into the study.
• Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy.
• Women with pregnancy or breast-feeding.
• Women of childbearing potential and not using an adequate contraceptive method.
• Men and women in their pregnancy attempts.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
• History of any Glucagon-like peptide-1 (GLP-1) treatment within 180 days.
• History of type 1 or type 2 diabetes mellitus.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR

Berlin, 13597, Germany

Location

MeSH Terms

Conditions

Obesity

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2025
• First Posted: July 23, 2025
• Study Start: August 8, 2025
• Primary Completion: December 18, 2025
• Study Completion: December 18, 2025
• Last Updated: April 27, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)